Alcon reported results for the third quarter of 2026, ended in September, with earnings above analyst estimates. Despite the earnings beat, the company’s shares fell 5% on November 11. Alcon narrowed its full-year financial outlook range, weighing on the stock.
The company kept its annual sales growth outlook at about 6%, while unit results showed a split between declines in implantables and growth in consumables and equipment.
Read the full storyThe company raised its sales growth forecast to about 6% in constant currencies, while implant sales fell amid competitive pressure on its lenses in the United States.
Third-quarter sales rose 5%, while the company lowered the upper end of its 2026 core EPS growth forecast to 14% amid competitive pressures in some areas.